Gelonghui, January 5th丨Dongyangguang Pharmaceutical (06887.HK) announced that HECN30227 is a first-in-class new drug independently developed by the group with global intellectual property rights. It can simultaneously eliminate hepatitis B surface antigen (HBsAg) derived from cccDNA and intDNA. Preclinical data show that HECN30227 exhibits pan-genotypic activity, effectively reducing HBsAg levels, maintaining significant efficacy against nucleoside drug-resistant strains, and demonstrating superior in vivo and in vitro efficacy compared to clinical competitors. HECN30227 utilizes the group’s uniquely designed HEC-GalNova (N-acetylgalactosamine) liver-targeting delivery system, which achieves precise and efficient liver delivery while significantly reducing off-target risks. To date, HECN30227 has completed enrollment of the first domestic subject.
Important research findings on the preclinical combination therapy of HECN30227 with the company's self-developed immunomodulator HEC191834 have been selected for the "Poster of Distinction" at the 2025 American Association for the Study of Liver Diseases (AASLD) Annual Meeting. This designation is awarded only to results ranking in the top 10%, signifying high recognition from an authoritative international academic institution of the clinical development potential of the HECN30227 combination therapy.
Since 2022, the group has ventured into the small nucleic acid field, establishing a comprehensive R&D platform covering "target discovery - sequence design and synthesis - chemical modification - delivery technology - biological evaluation," positioning its R&D capabilities among the top tier domestically. Relying on this robust technical platform, the company has filed over 50 patent applications and laid out more than 10 small nucleic acid pipelines, spanning four areas: anti-infectives, cardio-renal-metabolic, respiratory, and oncology. The company plans to advance multiple small nucleic acid drugs into clinical stages annually, continuously reinforcing its leading-edge technological position in the small nucleic acid therapeutic domain.
From the Phase I clinical trial of the hepatitis B siRNA therapy HECN30227 to diverse deployments such as dual targets, fat targeting, lung targeting, and AOC, the group is spearheading China's small nucleic acid drug innovation wave through a multidimensional layout of "technology + pipeline + industrialization." Moving forward, the group will continue to invest heavily in its small nucleic acid technology platform, accelerating solutions for unmet clinical needs and bringing globally leading treatment options made in China to patients worldwide.
